<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168221">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01969799</url>
  </required_header>
  <id_info>
    <org_study_id>CAP-01-102</org_study_id>
    <secondary_id>2013-002855-13</secondary_id>
    <nct_id>NCT01969799</nct_id>
  </id_info>
  <brief_title>Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative Pneumonia</brief_title>
  <acronym>IASIS</acronym>
  <official_title>A Randomized Blinded, Placebo-Controlled, Phase 2 Study of Aerosolized Amikacin and Fosfomycin Delivered Via the Investigational eFlow® Inline System in Mechanically Ventilated Patients With Gram-negative Bacterial Pneumonia (IASIS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardeas Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardeas Pharma</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the safety and efficacy of adjunctive therapy with the Amikacin fosfomycin
      inhalation system (AFIS) versus aerosolized placebo to treat Gram-negative pneumonia in
      mechanically ventilated patients receiving IV antibiotics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary purpose of this study is to demonstrate the safety and efficacy of the amikacin
      fosfomycin inhalation system (AFIS).  AFIS consists of amikacin solution  and fosfomycin
      solution, delivered by aerosol to the lungs via the PARI Investigational eFlow Inline System
      (eFlow Inline System).  All patients will receive a standardized course of intravenous (IV)
      antibiotics for a minimum of 7 days.  Patients will be randomized to receive 10 days of
      treatment with either AFIS or placebo, in addition to the IV therapy.  The primary efficacy
      endpoint is defined as the change from baseline in the Clinical Pulmonary Infection Score
      (CPIS) during the randomized course of study drug.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline in Clinical Pulmonary Infection Score (CPIS) during the planned 10-day treatment period.</measure>
    <time_frame>10 day treatment period.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Daily CPIS will be determined by one blinded, central reviewer in order to minimize inter-observer variability.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite endpoint of mortality and ventilator-free days</measure>
    <time_frame>Day 1- Day 28</time_frame>
    <safety_issue>No</safety_issue>
    <description>The hierarchical composite endpoint of mortality and ventilator-free days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days free of  mechanical ventilation from Day 1 through Day 28</measure>
    <time_frame>Day 1 - Day 28</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ICU days from Day 1 through Day 28</measure>
    <time_frame>Day 1 - Day 28</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological response rates in patients positive for multi-drug resistant Gram-negative bacteria</measure>
    <time_frame>Day 14</time_frame>
    <safety_issue>No</safety_issue>
    <description>Microbiological response rates at Day 14 in patients whose pre-study treatment bronchoalveolar lavage (BAL) was positive for multi-drug resistant Gram-negative bacteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality from Day 1 through Day 28</measure>
    <time_frame>Day 1 - Day 28</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical relapse rate</measure>
    <time_frame>Day 11 - Day 28</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical relapse rates (defined as a new episode of pneumonia requiring reinstitution of IV antibiotics) from Day 11 through Day 28</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Pneumonia, Bacterial</condition>
  <arm_group>
    <arm_group_label>Amikacin fosfomycin inhalation solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg of amikacin and 120 mg of fosfomycin twice daily for 10 days to be administered by aerosol via the eFlow Inline System.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aerosolized placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Aerosolized placebo twice daily for 10 days administered using the eFlow Inline System</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amikacin fosfomycin inhalation solution</intervention_name>
    <description>300 mg of amikacin and 120 mg of fosfomycin twice daily for 10 days to be administered by aerosol via the eFlow Inline System</description>
    <arm_group_label>Amikacin fosfomycin inhalation solution</arm_group_label>
    <other_name>Amikacin fosfomycin inhalation system (AFIS)</other_name>
    <other_name>eFlow Inline System</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aerosolized placebo</intervention_name>
    <description>Placebo twice daily for 10 days to be administered by aerosol the eFlow Inline System</description>
    <arm_group_label>Aerosolized placebo</arm_group_label>
    <other_name>Aerosolized placebo</other_name>
    <other_name>eFlow Inline System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and non-pregnant, non-lactating females, ≥ 18 years and ≤ 80 years of age

          -  Intubated and mechanically ventilated

          -  Diagnosis of pneumonia, defined as presence of a new or progressive infiltrate(s) on
             chest radiograph (within 24 hours prior to screening), as determined by the treating
             physician

          -  Signs of infection (within 24 hours prior to screening):

               1. Fever (&gt; 38ºC or &gt; 100.4ºF); or

               2. Leukopenia (&lt; 4,000 WBC/mm3) or leukocytosis (≥ 12,000 WBC/mm3)

          -  Impaired oxygenation (within 24 hours prior to screening):

             a. PaO2/FiO2 ≤ 300 mmHg

          -  Acute Physiology and Chronic Health Evaluation (APACHE) II score &gt; 10 on the day of
             ICU admission

          -  Presence, or high suspicion, of Gram-negative organism(s) by either Gram stain or
             culture of respiratory secretions from a sample obtained within the previous 7 days
             (enrollment can occur before culture results are available)

        Exclusion Criteria:

          -  History of hypersensitivity to amikacin, other aminoglycosides, fosfomycin, imipenem,
             meropenem, or colistin

          -  Received systemic antibiotic therapy for this episode of Gram-negative pneumonia for
             greater than 48 hours at the time of randomization

          -  PaO2/FiO2 ≤ 100 mmHg plus diffuse infiltrates on Chest X-ray

          -  Septic shock (defined as severe sepsis plus refractory [&gt; 6 hours duration]
             hypotension)

          -  Any of the following conditions that interfere with the assessment or interpretation
             of the diagnosis or response to therapy:

               1. chest trauma with ongoing loss of stability of the thoracic cage following a
                  fracture of the sternum, ribs, or both;

               2. increased amounts of fluid in the lung cavities requiring chest tube drainage;

               3. lung cancer within the last 2 years;

               4. lung abscess(s);

               5. anatomical bronchial obstruction;

               6. suspected atypical pneumonia;

               7. chemical pneumonitis (e.g., inhalation injury);

               8. cystic fibrosis

          -  Immunocompromised patients, including those with neutropenia NOT due to the current
             infection (absolute neutrophil count &lt; 500/mm3), leukemia, lymphoma, human
             immunodeficiency virus (HIV) infection with CD4 count &lt; 200 cells/mm3, or
             splenectomy; those who are early post-transplantation (&lt; 3 months post-transplant, or
             &gt; 3 months post-transplant with evidence of organ rejection by clinical criteria,
             pathologic confirmation, or modification of immunosuppression within the past 4
             weeks), are on cytotoxic chemotherapy, or are on high-dose steroids (e.g., &gt; 40 mg of
             prednisone or its equivalent [&gt; 160 mg hydrocortisone, &gt; 32 mg methylprednisolone, &gt;
             6 mg dexamethasone, &gt; 200 mg cortisone] daily for &gt; 2 weeks)

          -  Evidence of significant renal impairment (serum creatinine &gt; 2.0 mg/dL within 24
             hours prior to screening)

          -  Evidence of ototoxicity (history of hearing aid use prior to current hospitalization)

          -  Evidence of hepatotoxicity (alanine aminotransferase [ALT] or aspartate
             aminotransferase [AST] &gt;3X the upper limit of normal value within 24 hours prior to
             screening)

          -  Positive urine and/or serum beta-hCG pregnancy test (only in women of reproductive
             age)

          -  On mechanical ventilation for &gt; 28 days

          -  Head injury or stroke that will likely require continued mechanical ventilation after
             resolution of pneumonia, or Glasgow Coma Scale score ≤ 3 at Screening

          -  Participating in or has participated in other investigational interventional studies
             (drug or device) within the last 30 days (or 5 times the half-life of the previously
             administered investigational compound, whichever is longer)  prior to study treatment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marin Kollef, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cardeas Clinical Trials</last_name>
    <phone>206 973 1026</phone>
    <email>info@cardeaspharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Bay Pines</city>
        <state>Florida</state>
        <zip>77344</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Hazard</city>
        <state>Kentucky</state>
        <zip>41701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>21686</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>60198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Limoges</city>
        <state>Limousin</state>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Orléans</city>
        <state>Loiret</state>
        <zip>45000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <state>Meurthe-et-Moselle</state>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Bron</city>
        <state>Rhône</state>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulon</city>
        <state>Var</state>
        <zip>83056</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Vesoul</city>
        <zip>70000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Colombes</city>
        <state>Île-de-France</state>
        <zip>92701</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Athen</city>
        <state>Athens</state>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Alexandroupolis</city>
        <state>Evros</state>
        <zip>68100</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Athens</city>
        <zip>10676</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Athens</city>
        <zip>15227</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ioannina</city>
        <zip>45500</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Larisa</city>
        <zip>41334</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Gyula</city>
        <state>Békés</state>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Debrecen</city>
        <state>Hajdú-Bihar</state>
        <zip>4012</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Debrecen</city>
        <state>Hajdú-Bihar</state>
        <zip>4043</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1115</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1081</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1106</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kistarcsa</city>
        <zip>2143</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Pécs</city>
        <zip>7623</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan</city>
        <zip>00921</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Palma de Mallorca</city>
        <state>Baleares</state>
        <zip>07010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Getafe</city>
        <state>Comunidad de Madrid</state>
        <zip>28905</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Anakara</city>
        <state>Ankara</state>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Törökbálint</city>
        <state>Pest</state>
        <zip>2045</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ankara</city>
        <zip>06110</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Istanbul</city>
        <zip>34760</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Trabzon</city>
        <zip>61080</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>France</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Spain</country>
    <country>Turkey</country>
  </location_countries>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/antibiotics.html</url>
    <description>MedlinePlus related topics: Antibiotics</description>
  </link>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/pneumonia.html</url>
    <description>MedlinePlus related topics: Pneumonia</description>
  </link>
  <link>
    <url>http://druginfo.nlm.nih.gov/drugportal/ProxyServlet?mergeData=true&amp;objectHandle=DBMaint&amp;APPLICATION_NAME=drugportal&amp;actionHandle=default&amp;nextPage=jsp/drugportal/ResultScreen.jsp&amp;TXTSUPERLISTID=0037517285&amp;QV1=AMIKACIN</url>
    <description>Drug Information available for amikacin</description>
  </link>
  <link>
    <url>http://druginfo.nlm.nih.gov/drugportal/ProxyServlet?mergeData=true&amp;objectHandle=DBMaint&amp;APPLICATION_NAME=drugportal&amp;actionHandle=default&amp;nextPage=jsp/drugportal/ResultScreen.jsp&amp;TXTSUPERLISTID=0023155024&amp;QV1=FOSFOMYCIN</url>
    <description>Drug information available for fosfomycin</description>
  </link>
  <link>
    <url>http://www.clinicaltrials.gov/ct2/info/fdalinks</url>
    <description>U.S. FDA Resources</description>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 22, 2014</lastchanged_date>
  <firstreceived_date>October 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gram-negative pneumonia</keyword>
  <keyword>Aerosol antibiotics</keyword>
  <keyword>Mechanical ventilation</keyword>
  <keyword>Amikacin</keyword>
  <keyword>Fosfomycin</keyword>
  <keyword>Pneumonia, Bacterial</keyword>
  <keyword>Pneumonia</keyword>
  <keyword>Bacterial Infections</keyword>
  <keyword>Lung Diseases</keyword>
  <keyword>Respiratory Tract Diseases</keyword>
  <keyword>Respiratory Tract Infections</keyword>
  <keyword>Anti-Bacterial Agents</keyword>
  <keyword>Anti-Infective Agents</keyword>
  <keyword>Therapeutic Uses</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pneumonia, Bacterial</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amikacin</mesh_term>
    <mesh_term>Fosfomycin</mesh_term>
    <mesh_term>Anti-Infective Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
